 REDWOOD CITY, Calif.--BUSINESS WIRE--Guardant Health, Inc. Nasdaq: GH announced that the New York State Department of Health Clinical Laboratory Evaluation Program CLEP has approved the Guardant RevealTM liquid biopsy test for the detection and monitoring of minimal residual disease MRD in patients with early-stage cancer stage II and III. Guardant Reveal is the first blood-only test able to detect, with 7-day turnaround time, a patients status for residual disease, without the need f 